CD274 and neoplasm: The RATIONALE-305 clinical trial (Qiu et al., 2024) demonstrated that primary treatment with tislelizumab in combination with chemotherapy significantly improves OS compared to placebo with chemotherapy, particularly in patients with a PD-L1 tumor area proportion (TAP) ≥ 5% and among all participants.